Market closed
Eli Lilly/$LLY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
43,000
Website
Eli Lilly Metrics
BasicAdvanced
$707B
84.92
$9.25
0.43
$5.20
0.76%
Price and volume
Market cap
$707B
Beta
0.43
52-week high
$972.53
52-week low
$624.68
Average daily volume
3.7M
Dividend rate
$5.20
Financial strength
Current ratio
1.273
Quick ratio
0.63
Long term debt to equity
203.322
Total debt to equity
218.081
Dividend payout ratio (TTM)
54.12%
Interest coverage (TTM)
18.52%
Management effectiveness
Return on assets (TTM)
13.95%
Return on equity (TTM)
65.32%
Valuation
Price to earnings (TTM)
84.917
Price to revenue (TTM)
17.312
Price to book
49.63
Price to tangible book (TTM)
365.38
Price to free cash flow (TTM)
-405.54
Dividend yield (TTM)
0.66%
Forward dividend yield
0.76%
Growth
Revenue change (TTM)
27.41%
Earnings per share change (TTM)
67.52%
3-year revenue growth (CAGR)
13.76%
3-year earnings per share growth (CAGR)
12.19%
3-year dividend per share growth (CAGR)
15.20%
What the Analysts think about Eli Lilly
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Eli Lilly Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Eli Lilly News
AllArticlesVideos
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
CNBC Television·2 days ago
Thurgood Marshall College Fund receives $25 million grant from Lilly Endowment for HBCU capacity building
GlobeNewsWire·3 days ago
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
24/7 Wall Street·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Feb14
Eli Lilly
Dividend·Ex-dividend
Mar10
Eli Lilly
Dividend·Payment
$1.50
Per share
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $707B as of January 27, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 84.92 as of January 27, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of January 27, 2025, the dividend rate is $5.2 and the yield is 0.76%. Eli Lilly has a payout ratio of 54.12% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for March 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.